Цитологія і генетика 2019, том 53, № 5, 75-89
Cytology and Genetics 2019, том 53, № 5, 407–417, doi: https://www.doi.org/10.3103/S0095452719050062

«Двойной удар»: вирусный гепатит С у пациентов с генетическими нарушениями обмена железа

Даниленко Н.Г., Синявская М.Г., Лукашик С.П., Карпов И.А., Давыденко О.Г.

  1. Институт генетики и цитологии, НАН Беларуси, Минск, ул. Академическая, 27
  2. Белорусский государственный медицинский университет, Минск, 220116, пр­т Дзержинского, 83

Обзор посвящен особенностям развития хронического вирусного гепатита С в организме при наличии генетического дефекта в гене наследственного гемохроматоза (HFE), контролирующем метаболизм железа. Обсуждается влияние мутаций гена HFE на: подверженность пациента вирусной агрессии, развитие патологических процессов в печени при хроническом вирусном гепатите С, в том числе наиболее тяжелых осложнений – цирроза печени и гепатоклеточной карциномы, отзывчивость пациентов – носителей мутаций на терапию вирусного гепатита С.

РЕЗЮМЕ. Огляд присвячений особливостям розвитку хронічного вірусного гепатиту С в організмі при наявності генетичного дефекту в гені спадкового гемохроматозу (HFE), що контролює метаболізм заліза. Обговорюється вплив мутацій гена HFE на: схильність пацієнта до вірусної агресії; розвиток патологічних процесів у печінці при хронічному вірусному гепатиті С, в тому числі найбільш важких ускладнень – цирозу печінки і гепатоклітинної карциноми, чутливість пацієнтів – носіїв мутацій до терапії вірусного гепатиту С.

Ключові слова: мутации гена HFE, вирус гепатита С, хроническая вирусная инфекция, нарушение обмена железа
мутації гена HFE, вірус гепатиту С, хронічна вірусна інфекція, порушення обміну заліза

Цитологія і генетика
2019, том 53, № 5, 75-89

Current Issue
Cytology and Genetics
2019, том 53, № 5, 407–417,
doi: 10.3103/S0095452719050062

Повний текст та додаткові матеріали

Цитована література

1. Price, L. and Kowdley, K.V., The role of iron in the pathophysiology and treatment of chronic hepatitis C, Can. J. Gastroenterol., 2009, vol. 23, no. 12, pp. 822–828.

2. Tai, A.W., Benita, Y., Peng, L.F., Kim, S.-S., Sakamoto, N., Xavier, R.J., and Chung, R.T., A functional genomic screen identifies cellular cofactors of hepatitis C virus replication, Cell Host. Microbe, 2009, vol. 5, no. 3, pp. 298–307. https://doi.org/10.1016/j.chom.2009.02.001

3. Petruzziello, A., Marigliano, S., Loquercio, G., and Cacciapuoti, C., Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes, World J. Gastroenterol., 2016, vol. 22, no. 34, pp. 7824–7840. https://doi.org/10.3748/wjg.v22.i34.7824

4. Eisenbach, C., Gehrke, S.G., and Stremmel, W., Iron, the HFE gene, and hepatitis C, Clin. Liver. Dis., 2004, vol. 8, no. 4, pp. 775–785. https://doi.org/10.1016/jcld.2004.06.006

5. Wallace, D.F. and Subramaniam, V.N., Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim. Biophys. Acta, 2009, vol. 1790, no. 7, pp. 663–70. https://doi.org/10.1016/j.bbagen.2008.09.002

6. Houghton, M., The long and winding road leading to the identification of the hepatitis C virus, J. Hepatol., 2009, vol. 51, no. 5, pp. 939–948. https://doi.org/10.1016/jhep.2009.08.004

7. McGivern, D.R. and Lemon, S.M., Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer, Oncogene, 2011, vol. 30, no. 17, pp. 1969–1983. https://doi.org/10.1038/onc2010.594

8. Feder, J.N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D.A., Basava, A., Dormishian, F., Domingo, R., Jr., Ellis, M.C., Fullan, A., Hinton, L.M., Jones, N.L., Kimmel, B.E., Kronmal, G.S., Lauer, P., Lee, V.K., Loeb, D.B., Mapa, F.A., McClelland, E., Meyer, N.C., Mintier, G.A., Moeller, N., Moore, T., Morikang, E., Prass, C.E., Quintana, L., Starnes, S.M., Schatzman, R.C., Brunke, K.J., Drayna, D.T., Risch, N.J., Bacon, B.R., and Wolff, R.K., A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis, Nat. Genet., 1996, vol. 13, no. 4, pp. 399–408. https://doi.org/10.1038/ng0896-399

9. Waheed, A., Parkkila, S., Saarnio, J., Fleming, R.E., Zhou, X.Y., Tomatsu, S., Britton, R.S., Bacon, B.R., and Sly, W.S., Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum, Proc. Natl. Acad. Sci. U. S. A., 1999, vol. 96, no. 4, pp. 1579–1584.

10. Trinder, D., Olynyk, J.K., Sly, W.S., and Morgan, E.H., Iron uptake from plasma transferrin by the duodenum is impaired in the HFE knockout mouse, Proc. Natl. Acad. Sci. U. S. A., 2002, vol. 99, no. 8, pp. 5622–5626. https://doi.org/10.1073/pnas.082112299

11. Umbreit, J., Iron deficiency: a concise review, Am. J. Hematol., 2005, vol. 78, no. 3, pp. 225–231. https://doi.org/10.1002/ajh.20249

12. Drakesmith, H. and Prentice, A., Viral infection and iron metabolism, Nat. Rev. Microbiol., 2008, vol. 6, no. 7, pp. 541–552. https://doi.org/10.1038/nrmicro1930

13. Martinelli, A.L., Ramalho, L.N., and Zucoloto, S., Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease, J. Gastroenterol Hepatol., 2004, vol. 19, no. 1, pp. 91–98. https://doi.org/10.1111/j.1440-1746.2004.03255.x

14. Merryweather-Clarke, A.T., Pointon, J.J., Jouanolle, A.M., Rochette, J., and Robson, K.J., Geography of HFE C282Y and H63D mutations, Genet. Test., 2000, vol. 4, no. 2, pp. 183–198. https://doi.org/10.1089/10906570050114902

15. Vujic, M., Molecular basis of HFE-hemochromatosis, Front. Pharmacol., 2014, vol. 5, no. 42, pp. 1–6. https://doi.org/10.3389/fphar.2014.00042

16. Andrews, N.C., Hereditary hemochromatosis protein, HFE, interaction with transferring receptor, p. 2. Hereditary hemochromatosis protein, HFE, interaction with transferring receptor 2 suggests a molecular mechanism for mammalian iron sensing, J. Biol. Chem., 2006, vol. 281, no. 39, pp. 28494–28498. https://doi.org/10.1074/jbc.C600197200

17. Kiss, J., Herrmann, T., Galy, B., Martinache, S., Stolte, J., Grone, H.J., Stremmel, W., Hentze, M.W., and Muckenthaler, M.U., HFE acts in hepatocytes to prevent hemochromatosis, Cell Metab., 2008, vol. 7, no. 2, pp. 173–178.

18. Babitt, J.L. and Herbert, Y.L., The molecular pathogenesis of hereditary hemochromatosis seminars in liver disease, Semin. Liver. Dis., vol. 31, no. 3, pp. 280–292. https://doi.org/10.1055/s-0031-1286059

19. Valore, E.V. and Ganz, T., Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin, Blood Cells Mol. Dis., 2008, vol. 40, no. 1, pp. 132–138. https://doi.org/10.1016/j.bcmd.2007.07.009

20. Park, C.H., Valore, E.V., Waring, A.J., and Ganz, T., Hepcidin, a urinary antimicrobial peptide synthesized in the liver, J. Biol. Chem., 2001, vol. 276, no. 11, pp. 7806–7810. https://doi.org/10.1074/jbc.M008922200

21. Ganz, T., Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation, Blood, 2003, vol. 102, no. 3, pp. 783–788. https://doi.org/10.1182/blood-2003-03-0672

22. Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T., and Kaplan, J., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization, Science, 2004, vol. 306, no. 5704, pp. 2090–2093. https://doi.org/10.1126/science.1104742

23. Hentze, M.W., Muckenthaler, M.U., Galy, B., and Camaschella, C., Two to tango: Regulation of mammalian iron metabolism, Cell, 2010, vol. 142, no. 1, pp. 24–38. https://doi.org/10.1016/j.cell.2010.06.028

24. Silva, B. and Faustino, P., An overview of molecular basis of iron metabolism regulation and the associated pathologies, Biochim. Biophys. Acta, 2015, vol. 1852, no. 7, pp. 1347–1359. https://doi.org/10.1016/j.bbadis.2015.03.011

25. Sivitskaya, L.N. and Kushniarevich, A.I., Hereditary haemochromatosis: C282Y and H63D mutations frequencies of HFE gene in Belarus population, Proc. Natl. Acad. Sci. Belarus, 2007, vol. 6, no. 1, pp. 414–418.

26. Di Bisceglie, A.M., Axiotis, C.A., Hoofnagle, J.H., and Bacon, B.R., Measurements of iron status in patients with chronic hepatitis, Gastroenterology, 1992, vol. 102, no. 6, pp. 2108–2113.

27. Piperno, A., D’Alba R., Fargion S., Sampietro M., Parma S., Arosio V., Fare M., and Fiorelli, G., Liver iron concentration in chronic viral hepatitis: a study of 98 patients, Eur. J. Gastroenterol. Hepatol., 1995, vol. 7, no. 12, pp. 1203–1208.

28. Tung, B.Y., Emond, M.J., Bronner, M.P., Raaka, S.D., Cotler, S.J., and Kowdley, K.V., Hepatitis C, iron status, and disease severity: relationship with HFE mutations, Gastroenterology, 2003, vol. 124, no. 2, pp. 318–326. https://doi.org/10.1053/gast.2003.50046

29. Souza, R.F., Feakins, R., and Mears, L., Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C, Aliment. Pharmacol. Ther., 2005, vol. 21, no. 5, pp. 519–524. https://doi.org/10.1111/j.1365-2036.2005.02382.x

30. Silva, I.S., Perez, R.M., Oliveira, P.V., Cantagalo, M.I., Dantas, E., Sisti, C., Figueiredo-Mendes, C., Lanzoni, V.P., Silva, A., and Ferraz, M.L., Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study, J. Gastroenterol. Hepatol., 2005, vol. 20, no. 2, pp. 243–248. https://doi.org/10.1111/j.1440-1746.2004.03549.x

31. Isomura, T., Yano, M., Hayashi, H., and Sakamoto, N., Excess iron in the liver of patients with chronic hepatitis C, J. Clin. Electron. Microsc., 1992, vol. 25, pp. 231–237.

32. Fujita, N. and Takei, Y., Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C, J. Gastroenterol., 2007, vol. 42, no. 10, pp. 923–926. https://doi.org/10.1007/s00535-007-2110-4

33. Bassett, S.E., Di Bisceglie, A.M., Bacon, B.R., Sharp, R.M., Govindarajan, S., Hubbard, G.B., Brasky, K.M., and Lanford, R.E., Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees, Hepatology, 1999, vol. 29, no. 6, pp. 1884–1892. https://doi.org/10.1002/hep.510290623

34. Bonkovsky, H.L., Naishadham, D., Lambrecht, R.W., Chung, R.T., Hoefs, J.C., Nash, S.R., Rogers, T.E., Banner, B.F., Sterling, R.K., Donovan, J.A., Fontana, R.J., Di Bisceglie, A.M., Ghany, M.G., and Morishima, C., HALT-C Trial Group. Roles of Iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C, Gastroenterology, 2006, vol. 131, no. 5, pp. 1440–1451. https://doi.org/10.1053/j.gastro.2006.08.036

35. Pietrangelo, A., Hemochromatosis gene modifies course of hepatitis C viral infection, Gastroenterology, 2003, vol. 124, no. 5, pp. 1509–1523.

36. Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C., and Trautwein, C., STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo, Gastroenterology, 2007, vol. 132, no. 1, pp. 294–300. https://doi.org/10.1053/j.gastro.2006.10.018

37. Foka, P., Dimitriadis, A., Karamichalia, D.A., Kyratzopoulou, E., Giannimaras, D., Koskinas, J., Varaklioti, A., Mamalaki, A., and Georgopoulou, U., Alterations in the iron homeostasis network: a driving force for macrophage mediated hepatitis C virus persistency, Virulence, 2016, vol. 7, no. 6, pp. 679–690. https://doi.org/10.1080/21505594.2016.1175700

38. Kohjima, M., Yoshimoto, T., Enjoji, M., Fukushima, N., Fukuizumi, K., Nakamura, T., Kurokawa, M., Fujimori, N., Sasaki, Y., Shimonaka, Y., Murata, Y., Koyama, S., Kawabe, K., Haraguchi, K., Sumida, Y., Harada, N., Kato, M., Kotoh, K., and Nakamuta, M., Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver, World. J. Gastroenterol., 2015, vol. 21, no. 11, pp. 3291–3299. https://doi.org/10.3748/wjg.v21.i11.3291

39. Liu, H., Trinh, T.L., Dong, H., Keith, R., Nelson, D., and Liu, C., Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus, PLoS One, 2012, vol. 7, no. 10. e46631. https://doi.org/10.1371/journal.pone.0046631

40. Miura, K., Taura, K., Kodama, Y., Schnabl, B., and Brenner, D.A., Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity, Hepatology, 2008, vol. 48, no. 5, pp. 1420–1429. https://doi.org/10.1002/hep.22486

41. Pirisi, M., Scott, C.A., Avellini, C., Toniutto, P., Fabris, C., Soardo, G., Beltrami, C.A., and Bartoli, E., Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations, Am. J. Clin. Pathol., 2000, vol. 113, no. 4, pp. 546–554. https://doi.org/10.1309/TRB1-JXUJ-L9R6-9NHX

42. Geier, A., Reugels, M., Weiskirchen, R., Wasmuth, H.E., Dietrich, C.G., Siewert, E., Gartung, C., Lorenzen, J., Bosserhoff, A.K., Brugmann, M., Gressner, A.M., Matern, S., and Lammert, F., Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C, Liver Int., 2004, vol. 24, no. 4, pp. 285–294. https://doi.org/10.1111/j.1478-3231.2004.0928.x

43. Erhardt, A., Maschner-Olberg, A., Mellenthin, C., Kappert, G., Adams, O., Donner, A., Willers, R., Niederau, C., and Haussinger, D., HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis, J. Hepatol., 2003, vol. 38, no. 3, pp. 335–342.

44. Mills, P.R., The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C, Gut, 2002, vol. 50, no. 2, pp. 248–252.

45. Lebray, P., Zylberberg, H., Hue, S., Poulet, B., Carnot, F., Martin, S., Chretien, Y., Pol., S., Caillat-Zuckman, S., Brechot, C., and Nalpas, B., Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C, J. Viral. Hepatitis, 2004, vol. 11, no. 2, pp. 175–182.

46. Gattoni, A., Parlato, A., Vangieri, B., Bresciani, M., Derna, R., and Baldassarre, R., Role of hemochromatosis genes in chronic hepatitis C, Clinica Terapeutica, 2006, vol. 157, no. 1, pp. 61–68.

47. Piperno, A., Vergani, A., Malosio, I., Parma, L., Fossati, L., Ricci, A., Bovo, G., Boari, G., and Mancia, G., Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations, Hepatology, 1998, vol. 28, no. 4, pp. 1105–1109. https://doi.org/10.1002/hep.510280427

48. Smith, B.C., Gorve, J., Guzail, M.A., Day, C.P., Daly, A.K., Burt, A.D., and Bassendine, M.F., Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C, Hepatology, 1998, vol. 27, no. 6, pp. 1695–1699. https://doi.org/10.1002/hep.510270631

49. Martinelli, A.L., Franco, R.F., Villanova, M.G., Figueiredo, J.F., Secaf, M., Tavella, M.H., Ramalho, L.N., Zucoloto, S., and Zago, M.A., Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?, Acta Haematol., 2000, vol. 102, no. 3, pp. 152–156. https://doi.org/10.1159/000040991

50. Bonkovsky, H.L., Troy, N., McNeal, K., Banner, B.F., Sharma, A., Obando, J., Mehta, S., Koff, R.S., Liu, Q., and Hsieh, C.C., Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C, J. Hepatol., 2002, vol. 37, no. 6, pp. 848–854.

51. Hezode, C., Cazeneuve, C., Coue, O., Roudot-Thoraval, F., Lonjon, I., Bastie, A., Duvoux, C., Pawlotsky, J.M., Zafrani, E.S., Amselem, S., and Dhumeaux, D., Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J. Hepatol., 1999, vol. 31, no. 6, pp. 979–84.

52. Negro, F., Samii, K., Rubbia-Brandt, L., Quadri, R., Male, P.J., Zarski, J.P., Baud, M., Giostra, E., Beris, P., and Hadengue, A., Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis, J. Med. Virol., 2000, vol. 60, no. 1, pp. 21–27.

53. Bataller, R., North, K.E., and Brenner, D.A., Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal, Hepatology, 2003, vol. 37, no. 3, pp. 493–503. https://doi.org/10.1053/jhep.2003.50127

54. Richardson, M.M., Powell, E.E., Barrie, H.D., Clouston, A.D., Purdie, D.M., and Jonsson, J.R., A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C, J. Med. Genet., 2005, vol. 42. e45. https://doi.org/10.1136/jmg.2005.032557

55. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S.Y., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson, C., Baddo, L.M., Barker-Collo, S., Bartels, D.H., Bell, M.L., Benjamin, E.J., Bennett, D., Bhalla, K., Bikbov, B., Bin Abdulhak, A., Birbeck, G., Blyth, F., Bolliger, I., Boufous, S., Bucello, C., Burch, M., Burney, P., Carapetis, J., Chen, H., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., Colquhoun, S., Colson, K.E., Condon, J., Connor, M.D., Cooper, L.T., Corriere, M., Cortinovis, M., de Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.H., Cross, M., Dabhadkar, K.C., Dahodwala, N., De Leo, D., Degenhardt, L., Delossantos, A., Denenberg, J., Des Jarlais, D.C., Dharmaratne, S.D., Dorsey, E.R., Driscoll, T., Duber, H., Ebel, B., Erwin, P.J., Espindola, P., Ezzati, M., Feigin, V., Flaxman, A.D., Forouzanfar, M.H., Fowkes, F.G., Franklin, R., Fransen, M., Freeman, M.K., Gabriel, S.E., Gakidou, E., Gaspari, F., Gillum, R.F., Gonzalez-Medina, D., Halasa, Y.A., Haring, D., Harrison, J.E., Havmoeller, R., Hay, R.J., Hoen, B., Hotez, P.J., Hoy, D., Jacobsen, K.H., James, S.L., Jasrasaria, R., Jayaraman, S., Johns, N., Karthikeyan, G., Kassebaum, N., Keren, A., Khoo, J.P., Knowlton, L.M., Kobusingye, O., Koranteng, A., Krishnamurthi, R., Lipnick, M., Lipshultz, S.E., Ohno, S.L., Mabweijano, J., MacIntyre, M.F., Mallinger, L., March, L., Marks, G.B., Marks, R., Matsumori, A., Matzopoulos, R., Mayosi, B.M., McAnulty, J.H., McDermott, M.M., McGrath, J., Mensah, G.A., Merriman, T.R., Michaud, C., Miller, M., Miller, T.R., Mock, C., Mocumbi, A.O., Mokdad, A.A., Moran, A., Mulholland, K., Nair, M.N., Naldi, L., Narayan, K.M., Nasseri, K., Norman, P., O’Donnell, M., Omer, S.B., Ortblad, K., Osborne, R., Ozgediz, D., Pahari, B., Pandian, J.D., Rivero, A.P., Padilla, R.P., Perez-Ruiz, F., Perico, N., Phillips, D., Pierce, K., Pope, C.A., Porrini, E., Pourmalek, F., Raju, M., Ranganathan, D., Rehm, J.T., Rein, D.B., Remuzzi, G., Rivara, F.P., Roberts, T., De Leon, F.R., Rosenfeld, L.C., Rushton, L., Sacco, R.L., Salomon, J.A., Sampson, U., Sanman, E., Schwebel, D.C., Segui-Gomez, M., Shepard, D.S., Singh, D., Singleton, J., Sliwa, K., Smith, E., Steer, A., Taylor, J.A., Thomas, B., Tleyjeh, I.M., Towbin, J.A., Truelsen, T., Undurraga, E.A., Venketasubramanian, N., Vijayakumar, L., Vos, T., Wagner, G.R., Wang, M., Wang, W., Watt, K., Weinstock, M.A., Weintraub, R., Wilkinson, J.D., Woolf, A.D., Wulf, S., Yeh, P.H., Yip, P., Zabetian, A., Zheng, Z.J., Lopez, A.D., Murray, C.J., AlMazroa, M.A., and Memish, Z.A. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 2012, vol. 380, no. 9859, pp. 2095–2128. https://doi.org/10.1016/S0140-6736(12)61728-0

56. Bruix, J. and Sherman, M., Management of hepatocellular carcinoma: an update, Hepatology, 2011, vol. 53, no. 3, pp. 1020–1022. https://doi.org/10.1002/hep.24199

57. King, L.Y., Canasto Chibuque, C., Johnson, K.B., Yip, S., Chen, X., Kojima, K., Deshmukh, M., Venkatesh, A., Tan, P.S., Sun, X., Villanueva, A., Sangiovanni, A., Nair, V., Mahajan, M., Kobayashi, M., Kumada, H., Iavarone, M., Colombo, M., Fiel, M.I., Friedman, S.L., Llovet, J.M., Chung, R.T., and Hoshida, Y.A., Genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration, Gut, 2015, vol. 64, no. 8, pp. 1296–1302. https://doi.org/10.1136/gutjnl-2014-307862

58. Bonkovsky, H.L., Jawaid, Q., Tortorelli, K., LeClair, P., Cobb, J., Lambrecht, R.W., and Banner, B.F., Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis, J. Hepatol., 1999, vol. 31, no. 3, pp. 421–429.

59. Moczulski, D.K., Grzeszczak, W., and Gawlik, B., Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy, Diabetes Care, 2001, vol. 24, no. 7, pp. 1187–1191.

60. Melis, M.A., Cau, M., Deidda, F., Barella, S., Cao, A., and Galanello, R., H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers, Haematologica, 2002, vol. 87, no. 3, pp. 242–245.

61. Tannapfel, A., Stolzel, U., Kostler, E., Melz, S., Richter, M., Keim, V., Schuppan, D., and Wittekind, C., C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients, Virchows Arch., 2001, vol. 439, no. 1, pp. 1–5.

62. Lee, D.W., Andersen, J.K., and Kaur, D., Iron dysregulation and neurodegeneration: the molecular connection, Mol. Interv., 2006, vol. 6, no. 2, pp. 89–97. https://doi.org/10.1124/mi.6.2.6

63. Xia, J., Xu, H., Jiang, H., and Xie, J., The association between the C282Y and H63D polymorphisms of HFE gene and the risk of Parkinson’s disease: a meta-analysis, Neurosci. Lett., 2015, vol. 595, pp. 99–103. https://doi.org/10.1016/j.neulet.2015.04.010

64. Lian, J., Xu, L., and Huang, Y., Le Y., Jiang D., Yang X., Xu W., Huang X., Dong C., Ye M., Zhou J., Duan S., Meta-analyses of HFE variants in coronary heart disease, Gene, 2013, vol. 527, no. 1, pp. 167–173. https://doi.org/10.1016/j.gene.2013.06.034

65. Ellervik, C., Tybjaerg-Hansen, A., and Appleyard, M., Hereditary hemochromatosis genotypes and risk of ischemic stroke, Neurology, 2007, vol. 68, no. 13, pp. 1025–1031. https://doi.org/10.1212/01.wnl.0000257814.77115.d6

66. Sini, M., Sorbello, O., Civolani, A., and Demelia, L., Hemochromatosis gene mutations: prevalence and effects on pegylated-interferon and ribavirin therapy response in chronic hepatitis C in Sardinia, J. Clin. Exp. Hepatol., 2012, vol. 2, no. 3, pp. 211–217. https://doi.org/10.1016/j.jceh.2012.06.004

67. Mazzanti, R., Arena, U., and Tassi, R., Hepatocellular carcinoma: where are we?, World J. Exp. Med., 2016, vol. 6, no. 1, pp. 21–36. https://doi.org/10.5493/wjem.v6.i1.21

68. Della, CorteC., Aghemo, A., and Colombo, M., Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies, World J. Gastroenterol., 2013, vol. 19, no. 9, pp. 1359–1371. https://doi.org/10.3748/wjg.v19.i9.1359

69. World Health Organization. Mortality database. http://www.who.int/whosis/en.

70. Bruno, S., Crosignani, A., Maisonneuve, P., Rossi, S., Silini, E., and Mondelli, M.U., Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study, Hepatology, 2007, vol. 46, no. 5, pp. 1350–6. https://doi.org/10.1002/hep.21826

71. Lauret, E., Rodriguez, M., Gonzalez, S., Lina-res, A., Lopez-Vazquez, A., Martinez-Borra, J., Rodrigo, L., and Lopez-Larrea, C., HFE gene mutations in alcoholic and virus related cirrhotic patients with hepatocellular carcinoma, Am. J. Gastroenterol., 2002, vol. 97, no. 4, pp. 1016–10121. https://doi.org/10.1111/j.1572-0241.2002.05553.x

72. Jin, F., Qu Li-Shuai, Shen X.Z., Association between C282Y and H63Dmutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis, J. Exp. Clin. Cancer Res., 2010, vol. 29, no. 1, p. 18. https://doi.org/10.1186/1756-9966-29-18

73. Nahon, P., Sutton, A., Rufat, P., Simon, C., Trinchet, J.C., Gattegno, L., Beaugrand, M., and Charnaux, N., Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis, World J. Gastroenterol., 2008, vol. 14, no. 5, pp. 713–719. https://doi.org/10.3748/wjg.14.713

74. Kew, M.C., Hepatic iron overload and hepatocellular carcinoma, Cancer Lett., 2009, vol. 286, no. 1, pp. 38–43. https://doi.org/10.1016/j.canlet.2008.11.001

75. Marshall, A., Lukk, M., Kutter, C., Davies, S., Alexander, G., and Odom, D.T., Global gene expression profiling reveals Spink1 as a potential hepatocellular carcinoma marker, PLoS One, 2013, vol. 8, no. 3, e59459. https://doi.org/10.1371/journal.pone.0059459

76. Jiang, S., Yang, Z., Li, W., Li, X., Wang, Y., Zhang, J., Xu, C., Chen, P.J., Hou, J., McCrae, M.A., Chen, X., Zhuang, H., and Lu, F., Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis, PLoS One, 2012, vol. 7, no. 9, e40363. https://doi.org/10.1371/journal.pone.0040363

77. Cevik, O., Li, D., Baljinnyam, E., Manvar, D., Pimenta, E.M., Waris, G., Barnes, B.J., and Kaushik-Basu, N., Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma, J. Biol. Chem., 2017, vol. 292, no. 52, pp. 21676–21689. https://doi.org/10.1074/jbc.M117.792721

78. Furutani, T., Hino, K., Okuda, M., Gondo, T., Nishina, S., Kitase, A., Korenaga, M., Xiao, S.Y., Weinman, S.A., Lemon, S.M., Sakaida, I., and Okita, K., Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein, Gastroenterology, 2006, vol. 130, no. 7, pp. 2087–2098. https://doi.org/10.1053/j.gastro.2006.02.060

79. Hoshida, Y., Fuchs, B.C., Bardeesy, N., Baumert, T.F., and Chung, R.T., Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma, J. Hepatol., 2014, vol. 61, no. 10, pp. S79–S90. https://doi.org/10.1016/j.jhep.2014.07

80. Singal, A.G., Manjunath, H., Yopp, A.C., Beg, M.S., Marrero, J.A., Gopal, P., and Waljee, A.K., The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis, Am. J. Gastroenterol., 2014, vol. 109, no. 3, pp. 325–334. https://doi.org/10.1038/ajg.2013.476

81. El-Serag, H.B., Kanwal, F., Davila, J.A., Kramer, J., and Richardson, P., A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis, Gastroenterology, 2014, vol. 46, no. 5, pp. 1249–1255.

82. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., and Albrecht, J.K., Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, N. Engl. J. Med., 1998, vol. 339, no. 21, pp. 1485–1492.

83. Glue, P., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S.K., Salfi, M., Jacobs, S., and Clement, R.P., A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C, Hepatology, 2000, vol. 32, no. 3, pp. 647–653.

84. Manns, M.P., John, G., McHutchison, RustgiV.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., and Albrecht, J.K., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 2001, vol. 358, no. 9286, pp. 958–965.

85. Katano, Y., Honda, T., Hayashi, K., Ishigami, M., Itoh, A., Hirooka, Y., Nakano, I., and Goto, H., Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C, J. Gastroenterol. Hepatol., 2012, vol. 27, no. 6, pp. 1112–1116. https://doi.org/10.1111/j.1440-1746.2011.06976.x

86. Carvalho, I., Cardoso, C., Cordeiro, J.V., Azevedo, J.E., Neefjes, J., and de Sousa, M., HFE cross-talks with the MHC class I antigen presentation pathway, Blood, 2005, vol. 106, pp. 971–977. https://doi.org/10.1182/blood-2004-12-4640

87. Lawless, M., White, M., Mankan, A., O’Dwyer, M.J., and Norris, S., Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis, Tissue Antigens, 2007, vol. 70, no. 4, pp. 294–300. https://doi.org/10.1111/j.1399-0039.2007.00895.x

88. Li, S.H., Zhao, H., Ren, Y.Y., Liu, Y.Z., Song, G., Ding, P., Ding, Y.P., and Wang, G.Q., The H63D mutation of the hemochromatosis gene is associated with sustained virological response in chronic hepatitis C patients treated with interferon-based therapy: a meta-analysis, Tohoku J. Exp. Med., 2012, vol. 226, no. 4, pp. 293–299. https://doi.org/10.1620/tjem.226.293

89. Kato, J., Miyanishi, K., Kobune, M., Nakamura, T., Takada, K., Takimoto, R., Kawano, Y., Takahashi, S., Takahashi, M., Sato, Y., Takayama, T., and Niitsu, Y., Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C, J. Gastroenterol., 2007, vol. 42, no. 10, pp. 830–836. https://doi.org/10.1007/s00535-007-2095-z

90. Desai, T.K., Jamil, L.H., Balasubramaniam, M., Koff, R., and Bonkovsky, H.L., Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials, Dig. Dis. Sci., 2008, vol. 53, no. 3, pp. 815–822. https://doi.org/10.1007/s10620-007-9945-7

91. Nirei, K., Matsuoka, S., Nakamura, H., Matsumura, H., and Moriyama, M., Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C, Intern. Med., 2015, vol. 54, no. 2, pp. 107–117. https://doi.org/10.2169/internalmedicine.54.2715

92. Kazemi-Shirazi, L., Datz, C., Maier-Dobersberger, T., Kaserer, K., Hackl, F., Polli, C., Steindl, P.E., Penner, E., and Ferenci, P., The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C, Gastroenterology, 1999, vol. 116, no. 1, pp. 127–134.

93. Sampietro, M., Piperno, A., Lupica, L., Arosio, C., Vergani, A., Corbetta, N., Malosio, I., Mattioli, M., Fracanzani, A.L., Cappellini, M.D., Fiorelli, G., and Fargion, S., High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda, Hepatology, 1998, vol. 27, no. 1, pp. 181–184.

94. Dostalikova-Cimburova, M., Kratka, K., and Stransky, J., Iron overload and HFE gene mutations in Czech patients with chronic liver diseases, Dis. Markers, 2012, vol. 32, no. 1, pp. 65–72. https://doi.org/10.3233/DMA-2012-0861